Shared on17 Aug 25Fair value Decreased 5.23%
The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00. What's in the News Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Increased 12%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 3.93%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on11 Mar 25Fair value Increased 0.43%
AnalystConsensusTarget has increased revenue growth from 6.5% to 10.1%, increased profit margin from 9.8% to 15.3% and increased future PE multiple from 7.5x to 11.6x.